All medicinal products for human use manufactured or imported into Malta and the EU, including medicinal products intended for export, are to be manufactured in accordance with the principles and guidelines of Good Manufacturing Practice (GMP).
GMP is that part of quality assurance which ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorisation (MA). GMP is concerned with both production and quality control.
GMP inspections are conducted to assess compliance with EU GMP Guidelines as specified in the provisions of the Medicines Act, 2003 and relevant EU Directives. These inspections also ensure that the conditions of the manufacturing licence are being met. By ensuring that EU GMP standards are met during the production of medicinal products one is ensuring that medicines that reach the patient are safe, of good quality and efficacious. The inspection process is a vital safeguard to public health.
There are various types of GMP inspections:
GMP inspections include inspections for:
IMPs are a pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorisation when used or assembled (formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or when used to gain further information about the authorised form. Manufacture of IMPs has to be in accordance with EU GMP.
Any change to the packaging of medicinal products has to be conducted in accordance with EU GMP Guidelines and can only be done under a Manufacturing Licence specifying the type of repackaging activity being carried out.
Importation of a medicinal product from a country outside the European Union requires a Manufacturing Licence.
EU Directives specify an obligation for manufacturing authorisation holders to use as starting materials, only active substances which have been manufactured in accordance with the GMP guidelines for active substances. API manufacturers are issued with a GMP certificate only, unless the applicant specifically requests a manufacturing licence.
Quality control and microbiological laboratories, including stability testing of investigational and marketed medicinal products, is regarded as part of the medicinal manufacturing process. Laboratories providing this service have to be operating in compliance with GMP. Stand alone contract GMP laboratories do not hold their own manufacturer's licence but are named on the manufacturer's licence who is using their services.
EudraLex - Volume 4 Good manufacturing practice (GMP) Guidelines
S.L. 458.42 - Good Manufacturing Practice in Respect of Medicinal and Investigational Medicinal Products for Human Use Regulations.
S.L. 458.36 - Manufacture and Importation of Medicinal Products for Human Use (Amendment) Regulations.
S.L. 458.47 - Good Clinical Practice and Requirements for Manufacturing or Import Authorisation of Investigational Medicinal Products (Human Use) Regulations.
Application for a Manufacturer's/Importer's Licence for Medicinal Products and/or Investigational Medicinal Products for Human Use
Application for a Variation to a Manufacturer's, Importer's or Wholesale dealer's LicenceLuLu
Application for a Certificate for GMP Compliance of a Manufacturer
Application for Registration for API Import & Distribution Activity
Circulars
New requirements for importation of Active Pharmaceutical Ingredients (APIs)
Further information
Organisation Management Service (OMS) integration with EudraGMDP -Human and Veterinary industry preparedness for more information click here
For further information please send an email on inspectorate.adm@gov.mt